Introduction {#s1}
============

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death, with adenocarcinoma being one of the most common forms ([@B1]). Epidermal growth factor receptor (*EGFR*) mutations could be detected in 30--60% of Asian patients and 10--20% of Caucasian patients with lung cancer ([@B2]). Being as a driver oncogene, double-blinded randomized clinical trials have indicated that application of EGFR tyrosine kinase inhibitors (TKIs) are effective against NSCLC cases harboring *EGFR* mutations ([@B3]).

*EGFR* mutations most commonly occur in exon 19 or exon 21 within the EGFR tyrosine kinase domain. The rare *EGFR* mutations are usually not detected by the first-generation testing techniques. However, advanced precise detection techniques (e.g., next generation sequencing, NGS) enable the discovery of more rare *EGFR* mutations, including exons 18--25 kinase domain duplications (KDDs) ([@B4]). Herein, we reported a first case of an oncogenic EGFR-KDD in lung adenocarcinoma who were responsive to treatment with afatinib in Chinese populations.

Case Presentation {#s2}
=================

A 59-year-old male was referred to our hospital for detection of a right lung mass on physical examination. He had no history of pulmonary disease or smoking. A mass (2.3 × 1.8 cm) in the right lower lung was observed by computed tomography (CT) scan ([Figure 1A](#F1){ref-type="fig"}). F-18 fluorodeoxyglucose hypermetabolic speckles in fourth vertebral body; no hypermetabolic lesions were demonstrated in other sites, and a MRI of the brain or CT of the head with IV contrast was not performed. We detected a typical morphology for adenocarcinoma cells by hematoxylin and eosin (H&E) staining ([Figure 2](#F2){ref-type="fig"}). Immunohistochemical staining showed positive for the expression of NapsinA, TTF-1, and CK7. The patient was classified as stage IV (T~1~N~0~M~1~), in accordance to the 7th edition of TNM staging. The ARMS assay, the first-generation sequencing technique, revealed wild-type for sensitive *EGFR* mutations, including *EGFR* 18-21, and negative for *ALK* rearrangement or *ROS1* rearrangement. Then, a NGS analysis of the tumor biopsy identified a *EGFR*-KDD mutation (copy number 2.0) accompanied *TP53* p.R282W (frequency 13.0%) and *CTNNB1* p.S37Y (frequency 5.1%) in the tumor (Geneplus, Beijing, China) ([Figure 3](#F3){ref-type="fig"}), and PD-L1 staining was not done. Therefore, he underwent oral afatinib treatment (30 mg qd). Afterwards, the patient showed a stable tumor response to afatinib (1.9 × 1.4 cm) ([Figure 1B](#F1){ref-type="fig"}). Besides, there were no adverse events, including gastrointestinal reactions, hepatic and renal function, and cardiac damage. Currently, the disease is stable and treatment with afatinib continues for 10 months.

![Computed tomography (CT) scans before **(A)** and after **(B)** afatinib therapy.](fonc-10-00867-g0001){#F1}

![Hematoxylin and eosin (H&E) staining of lung biopsy showed a typical morphology for adenocarcinoma cells (H&E × 100).](fonc-10-00867-g0002){#F2}

![The *EGFR*-KDD is an oncogenic *EGFR* alteration. **(A)** The Integrative Genomics Viewer snapshot of paired NGS reads of tumor and matched blood. **(B)** Schematic representation of *EGFR*-KDD depicting the genetic and protein domain structures. ECD, extracellular domain; TM, transmembrane domain; KD1, first kinase domain; KD2, second kinase domain; C-term, carboxyl terminus. Blue, *EGFR* exons 18--25 \#1; orange, *EGFR* exons 18--25 \#2.](fonc-10-00867-g0003){#F3}

Discussion {#s3}
==========

Oncogenic *EGFR* mutations are detected in 30--60% of Asian patients and 10--20% of Caucasian patients. Such mutations are most detected as small in-frame deletions in exon 19 or point mutations in exon 21. Uncommon *EGFR* alterations, including rare point mutations and gene rearrangements, have also been reported previously ([@B5]).

*EGFR*-KDDs could activate EGFR signaling by forming an intra-molecule dimer ([@B6]). *EGFR*-KDD of exons 18--25, firstly discovered in a glioblastoma ([@B7]), has been recognized as a driver gene in lung cancer. In 2015, Baik et al. ([@B8]) first reported an *EGFR*-KDD in a female patient with a bronchoalveolar carcinoma and responsive to the first-generation EGFR-TKIs, including erlotinib and gefitinib. Another case reported a male patient with lung adenocarcinoma and an *EGFR*-KDD mutation detected with NGS, who had a preferable anti-tumor response to afatinib, a second-generation EGFR-TKI ([@B6]). Zhu et al. ([@B9]) reported the first case involving the presence of oncogenic *EGFR*-KDD in China, who had stable disease to treatment with an EGFR-TKI icotinib. Another case report of a prolonged multi-year response to gefitinib and then erlotinib has been described for advanced *EGFR*-KDD mutated lung adenocarcinoma ([@B8]). Therefore, it seems these *EGFR* variants are sensitive to first- and second- generation EGFR-TKIs. Consistently, *in vitro* study showed that *EGFR*-KDD is constitutively active, and computational modeling provides potential mechanistic support for its auto-activation ([@B9]). Herein, we for the first time detected EGFR-KDD in a Chinese patient who achieved sustained anti-tumor responses from treatment with afatinib.

Polymerase chain reaction (PCR) is frequently applied for detection of common *EGFR* variants in NSCLC patients, which is unable to identify some rare types of *EGFR* alterations ([@B10]). By contrast, NGS allows for multiplex testing and enables the detection of known as well as uncommon genomic events, as reported in this case ([@B11]). Thus, clinical treatment should improve with clinical diagnostics for multiple gene testing to provide personalized cancer therapy.

In summary, the present case increases the evidence supporting afatinib treatment of NSCLC patients harboring *EGFR*-KDD variants. The NGS assay provides a useful way to identify rare and uncommon *EGFR* gene mutations in NSCLC patients.
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